PTGX Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 27.14%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Protagonist Therapeutics, Inc. has a consensus price target of $89.77, signalling upside risk potential of 7.45%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 87.67%. Given that ADMA Biologics, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.216, which suggesting that the stock is 121.598% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.813%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 125.60x while ADMA Biologics, Inc.'s PE ratio is 17.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 24.39x versus 7.31x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 21.47%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Johnson & Johnson's return on equity of 33.27%.

Protagonist Therapeutics, Inc. has a consensus price target of $89.77, signalling upside risk potential of 7.45%. On the other hand Johnson & Johnson has an analysts' consensus of $199.56 which suggests that it could grow by 6.96%. Given that Protagonist Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics, Inc. is more attractive than Johnson & Johnson.

Protagonist Therapeutics, Inc. has a beta of 2.216, which suggesting that the stock is 121.598% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.876%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.72% to investors and pays a quarterly dividend of $1.30 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 125.60x while Johnson & Johnson's PE ratio is 18.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 24.39x versus 4.91x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of 38.89%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Protagonist Therapeutics, Inc. has a consensus price target of $89.77, signalling upside risk potential of 7.45%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $753.17 which suggests that it could grow by 14.55%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.216, which suggesting that the stock is 121.598% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.313, suggesting its less volatile than the S&P 500 by 68.714%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.4% to investors and pays a quarterly dividend of $0.88 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 125.60x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 24.39x versus 5.09x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -834.87% compared to Protagonist Therapeutics, Inc.'s net margin of -40.15%. Protagonist Therapeutics, Inc.'s return on equity of 7.15% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Protagonist Therapeutics, Inc. has a consensus price target of $89.77, signalling upside risk potential of 7.45%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 167.05%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc. has a beta of 2.216, which suggesting that the stock is 121.598% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.775, suggesting its less volatile than the S&P 500 by 22.489%.

Protagonist Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Protagonist Therapeutics, Inc. quarterly revenues are $4.7M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Protagonist Therapeutics, Inc.'s net income of -$39.3M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Protagonist Therapeutics, Inc.'s price-to-earnings ratio is 125.60x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics, Inc. is 24.39x versus 1.22x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.